secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K/A
Filed at:   2023-06-28T23:59:59+00:00
Accession:  0001140361-23-031820
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant corrects Immunovant TED Phase 3 data timeline to H1 2025; reports Q4 revenue $27.4M, loss $0.05/share
--------------------------------------------------------------------------------

- Corrected timeline for Immunovant's Phase 3 TED trials: topline data expected in H1 2025 (previously misstated).
- Q4 product revenue from VTAMA $13.7M; fiscal year VTAMA revenue $28.0M; over 170,000 prescriptions since launch.
- Cash and equivalents $1.7B as of March 31, 2023; cash runway into H2 2025.
- RVT-3101 Phase 2b UC data showed improved efficacy from week 14 to week 56; Phase 2 Crohn's study initiated.
- Net loss attributable to Roivant $33.6M ($0.05 per share) for Q4 vs $270.1M loss year ago; loss from continuing ops $175.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123031820/0001140361-23-031820-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123031820/brhc20055123_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-031820

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer